DigestRedComo funciona
Red
/
Empresas
Pe
No verificado

PeptiDream Inc.

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaIndustriaSalud

8 Comunicados de prensa

Ver todos los comunicados de prensa
11/06/2026
Industria
Ciencia
Medicina nuclear
Biotecnología
Farmacéutica
Oncología
Salud
Medicina - Varios
PeptiDream Announces First Dosing of Claudin18.2 Targeting Radiopharmaceutical Candidate 64Cu-PD-29875 in Patients with Gastric Cancer
Fuente
PeptiDream Inc.
Editor
Business Wire
1.00
0
11/06/2026
Industria
Ciencia
Medicina - Varios
Biotecnología
Medicina nuclear
Farmacéutica
Ir de compras
Salud
Oncología
PeptiDream, PDRadiopharma and Curium Group Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
Fuente
PeptiDream Inc.
Editor
Business Wire
1.00
0
20/04/2026
Industria
Salud
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Medicina nuclear
Farmacéutica
Biotecnología
PeptiDream Announces the Initiation of Phase 1 Clinical Trial by Its Collaboration Partner
Fuente
PeptiDream Inc.
Editor
Business Wire
1.00
0
18/12/2025
Industria
Biotecnología
Salud
Ciencia
Farmacéutica
PeptiDream and Alnylam Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration Demonstrating Peptide-Ligand Mediated Targeted siRNA Delivery to Specific Extrahepatic Tissues
Fuente
PeptiDream Inc.
Editor
Business Wire
1.00
0
17/12/2025
Industria
Biotecnología
Salud
Ciencia
Farmacéutica
PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of Psoriasis
Fuente
PeptiDream Inc.
Editor
Business Wire
1.00
0
28/03/2025
Industria
Sanidad
Medicina - Varios
Biología
Biotecnología
Medicina nuclear
Farmacéutica
Salud
Oncología
National Cancer Center Japan and PeptiDream: New Radiopharmaceuticals for Renal Cell Carcinoma
Fuente
PeptiDream Inc.
Editor
Business Wire
1.00
0
12/12/2024
Industria
Oncología
Salud
Sanidad
Ciencia
Farmacéutica
Biotecnología
PeptiDream Announces Second Internal Peptide Radiopharmaceutical Therapeutic Program Targeting Claudin 18.2 for the Potential Diagnosis and Treatment of Gastric Cancer
Fuente
PeptiDream Inc.
Editor
Business Wire
1.00
0
12/12/2024
Industria
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
PeptiDream Announces Preclinical Results Demonstrating Efficacy of Oral Myostatin Inhibitors in Preventing Loss of Lean Mass Associated with Semaglutide Treatment
Fuente
PeptiDream Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0